With employees.

With employees, he has a regression model developed for the prediction of the total antioxidant capacity of various anti-oxidant components allows serum, making the interrogation of large databases such as the National Health and Nutrition Examination Survey III.

‘.

Open clinical reports Discount Two-year data from the Phase I / II Retreatment study Tovaxin for Multiple Sclerosis – Opexa Therapeutics, Inc. , a cell therapy development and commercialization company, announced favorable safety and efficacy data for Tovaxi, the Company’s investigational T-cell vaccine therapy for multiple sclerosis , in the second year of the open-label clinical treatment trials in patients with MS.. Brian Loftus, 86 percent of patients Neurology and the principal investigator of the study, commented: ‘I am delighted to see that the subjects in the study experienced sustained positive clinical outcomes over a period of two years has been encouraging, especially to see a lack of progression of the disease in more than. Continue reading